0001209191-23-045095.txt : 20230808 0001209191-23-045095.hdr.sgml : 20230808 20230808200006 ACCESSION NUMBER: 0001209191-23-045095 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20230804 FILED AS OF DATE: 20230808 DATE AS OF CHANGE: 20230808 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Wigzell Hans Lennart Rudolf CENTRAL INDEX KEY: 0001492766 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-14895 FILM NUMBER: 231153039 MAIL ADDRESS: STREET 1: OSKAR BAECKSTROMSV.11 CITY: HAGERSTEN STATE: V7 ZIP: 12935 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Sarepta Therapeutics, Inc. CENTRAL INDEX KEY: 0000873303 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 930797222 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 415 CITY: CAMBRIDGE STATE: MA ZIP: 02142 BUSINESS PHONE: 617-274-4000 MAIL ADDRESS: STREET 1: 215 FIRST STREET STREET 2: SUITE 415 CITY: CAMBRIDGE STATE: MA ZIP: 02142 FORMER COMPANY: FORMER CONFORMED NAME: Sarepta Therapuetics, Inc. DATE OF NAME CHANGE: 20120712 FORMER COMPANY: FORMER CONFORMED NAME: AVI BIOPHARMA INC DATE OF NAME CHANGE: 19980930 FORMER COMPANY: FORMER CONFORMED NAME: ANTIVIRALS INC DATE OF NAME CHANGE: 19970123 4 1 doc4.xml FORM 4 SUBMISSION X0508 4 2023-08-04 0 0000873303 Sarepta Therapeutics, Inc. SRPT 0001492766 Wigzell Hans Lennart Rudolf 215 FIRST STREET, SUITE 415 CAMBRIDGE MA 02142 1 0 0 0 0 Common Stock 2023-08-04 4 M 0 15000 29.03 A 35994 D Common Stock 2023-08-04 4 S 0 15000 106.72 D 20994 D Stock Option (right to buy) 29.03 2023-08-04 4 M 0 15000 0.00 D 2015-02-28 2024-02-28 Common Stock 15000 0 D The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $106.42 to $107.04 per share. The reporting person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth above. /s/ Ryan Brown, as Attorney-in-Fact for Hans Wigzell 2023-08-08